Evaluation of 230 patients with relapsed/refractory deletion 17p chronic lymphocytic leukaemia treated with ibrutinib from 3 clinical trials

Patients with chronic lymphocytic leukaemia/small lymphocytic lymphoma (CLL/SLL) with deletion 17p [del(17p)] have poor outcomes with chemoimmunotherapy. Ibrutinib is indicated for the treatment of CLL/SLL, including del(17p) CLL/SLL, and allows for treatment without chemotherapy. This integrated an...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Br J Haematol
Hlavní autoři: Jones, Jeffrey, Mato, Anthony, Coutre, Steven, Byrd, John C., Furman, Richard R., Hillmen, Peter, Osterborg, Anders, Tam, Constantine, Stilgenbauer, Stephan, Wierda, William G., Heerema, Nyla A., Eckert, Karl, Clow, Fong, Zhou, Cathy, Chu, Alvina D., James, Danelle F., O'Brien, Susan M.
Médium: Artigo
Jazyk:Inglês
Vydáno: John Wiley and Sons Inc. 2018
Témata:
Haematological Malignancy
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6120509/
https://ncbi.nlm.nih.gov/pubmed/29873072
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bjh.15421
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky